Aerie Pharma seeks FDA OK for sale of Ireland-produced Rocklatan in U.S.

Aerie Pharmaceuticals (NASDAQ:AERI) has submitted a prior approval supplement (PAS) to the FDA.

If approved, the PAS will permit production of Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for sale in the U.S. in Aerie’s new manufacturing plant in Athlone, Ireland.

Aerie expects the PAS filing review to be completed within 60 days, with final PAS review in 4 months.

https://seekingalpha.com/news/3500394-aerie-pharma-seeks-fda-ok-sale-ireland-produced-rocklatan-u-s